FDA approves Amerigen’s generic cyclophosphamide
The Food and Drug Administration has approved Amerigen Pharmaceuticals’ abbreviated new drug application for two dosage strengths of its cyclophosphamide capsules. The drug, a generic of West-Ward’s product, is an anti-neoplastic agent indicated to treat various cancers.
Amerigen’s generic cyclophosphamide will be available in 25- and 50-mg capsules. The company said it plans to launch the drug soon, manufactured by Irvine Pharmaceuticals.
No comments found